Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

EZN-2208

 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

CamptothecinPolyethylene Glycols
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Phase 1 evaluation of EZN‐2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors
EZN‐2208 is a water‐soluble PEGylated conjugate of the topoisomerase inhibitor SN38, the active metabolite of irinotecan… Expand
2013
2013
Randomized phase 2 study of pegylated SN‐38 (EZN‐2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer
Irinotecan is cytotoxic in patients with advanced colorectal cancer (CRC). SN‐38 (10‐hydroxy‐7‐ethyl‐camptothecin) is the active… Expand
2013
2013
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer
PurposeThis study evaluated the tolerability, pharmacokinetics, and preliminary antitumor activity of EZN-2208, a water-soluble… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
2013
2013
Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors
SummaryBackground Anti-angiogenic therapies such as bevacizumab upregulate hypoxia-inducible factor-1α (HIF-1α), a possible… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
2012
2012
Safety, pharmacokinetics, and activity of EZN‐2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies
EZN‐2208 is a water‐soluble, polyethylene glycol drug conjugate of SN38, which is the active moiety of irinotecan. In this study… Expand
2012
2012
EZN-2208 (PEG-SN38) Overcomes ABCG2-Mediated Topotecan Resistance in BRCA1-Deficient Mouse Mammary Tumors
BRCA1 dysfunction in hereditary breast cancer causes defective homology-directed DNA repair and sensitivity towards DNA damaging… Expand
  • figure 1
  • figure 3
  • figure 4
2011
2011
Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects
Topoisomerase I inhibitors down-regulate HIF-1α leading to tumor growth inhibition, but only while maintaining sustained levels… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2010
Highly Cited
2010
Tumor Regression and Curability of Preclinical Neuroblastoma Models by PEGylated SN38 (EZN-2208), a Novel Topoisomerase I Inhibitor
Purpose: Treatment of neuroblastoma is successful in less than half of patients with high-risk disease. The antitumor activity of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
2009
2009
Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin’s lymphoma
This paper decribes the results of preclinical animal model studies successfully treating human lymphoma xenografts using a… Expand
  • table 1
  • figure 2
  • figure 1
Highly Cited
2008
Highly Cited
2008
Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11–Refractory Model
Purpose: Clinical development of SN38, the active metabolite of camptothecin-11 (CPT-11), has been hampered due to its poor… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE